Biologics Market Size, Share & Trends Analysis Report By Source (Microbial, Mammalian, Others), By Manufacturing (In-house, Outsourced), By Product (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense & RNAi Therapeutics, Others), By Disease Category (Oncology, Infectious Diseases, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others), By Type (Tumor Necrosis Factor (TNF) Inhibitor, T-cell Inhibitor, Selective Co-stimulation Modulators, Interleukin-6 (IL-6) or Interleukin-17 Blocker, Interleukin-1 (IL-1) Blocker, B-cell Inhibitor), By Drug Class (Monoclonal Antibody, Recombinant Insulin, Vaccine, Blood Factor, Human Growth Hormone, Erythropoietin, Fusion Protein, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Gene Therapy, Cell Therapy, Oligonucleotides, Peptide, Botulinum Toxin, Others), By Drug Type (Branded Drugs, Generic Drugs), By Mode of Purchase (Prescription Drugs, Over-the-counter (OTC) Drugs), By Dosage Form (Injection, Tablets, Others), By Route of Administration (Parenteral, Oral, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034